Surgical Innovations delivered a resilient FY25 performance in a challenging operating environment, with broadly flat revenues. While profitability weakened due to external headwinds (tariffs, supply chain disruption, NHS slowdown), the Group exits FY25 with clear operational momentum, improving mix, and early signs of revenue recovery into 2026. We introduce FY26 estimates showing 7% revenue growth and a return to positive Adj EBITDA.
